Noureddine Bouras | Nanobiotechnology | Excellence in Research Award

Prof. Dr. Noureddine Bouras | Nanobiotechnology | Excellence in Research Award

Lecturer | University of Ghardaia | Algeria

Prof. Dr. Noureddine Bouras is a distinguished microbiologist whose research focuses on actinobacteria biodiversity, microbial biotechnology, and the discovery of novel bioactive compounds from Saharan ecosystems. With over 2,300+ citations, an h-index of 28, and more than 100 published documents, his scholarly work has significantly advanced microbial taxonomy, antibiotic biosynthesis, and environmental microbiology. Prof. Dr. Noureddine Bouras has contributed to the identification and classification of numerous new microbial taxa from Algerian Saharan soils, expanding the global taxonomic database with over twenty novel species and genera within Actinopolyspora, Saccharothrix, Nocardiopsis, Streptosporangium, and Actinomadura. His pioneering studies on Saccharothrix algeriensis elucidated the regulation and biosynthesis of dithiolopyrrolone antibiotics, influencing new bioprocess engineering strategies for natural product development. His research integrates microbial genomics, bioinformatics, and secondary metabolite profiling to explore bioactive molecules with antimicrobial, antifungal, and plant growth-promoting properties. He has authored influential works in high-impact journals such as Journal of Natural Products, PLOS ONE, Food and Chemical Toxicology, and Current Microbiology, and co-authored multiple scientific books on microbiology and bioresource utilization. Prof. Dr. Noureddine Bouras has led and collaborated in several national and international R&D and funding projects, notably under the Algerian PNR program, focusing on biotechnological valorization of desert microbial resources. His expertise extends to applied microbiology, biocontrol, and biosynthesis of nanoparticles for antimicrobial applications. Recognized for his extensive contributions, he serves as reviewer and editorial board member for numerous peer-reviewed journals and has presented research in global scientific forums. His innovations in microbial taxonomy, antibiotic biosynthesis, and sustainable biotechnology position him as a leading figure in North African microbial research and global actinobacterial systematics.

Profiles: Scopus | ORCID | Google Scholar | ResearchGate | AD Scientific Index

Featured Publications

1. Riba, A., Bouras, N., Mokrane, S., Mathieu, F., Lebrihi, A., & Sabaou, N. (2010). Aspergillus section Flavi and aflatoxins in Algerian wheat and derived products. Food and Chemical Toxicology, 48(10), 2772–2777.

2. Bouras, H. D., Yeddou, A. R., Bouras, N., Hellel, D., Holtz, M. D., & Sabaou, N., et al. (2017). Biosorption of Congo red dye by Aspergillus carbonarius M333 and Penicillium glabrum Pg1: Kinetics, equilibrium and thermodynamic studies. Journal of the Taiwan Institute of Chemical Engineers, 80, 915–923.

3. Bouras, H. D., Isik, Z., Arikan, E. B., Yeddou, A. R., Bouras, N., Chergui, A., Favier, L., & Sabaou, N. (2021). Biosorption characteristics of methylene blue dye by two fungal biomasses. International Journal of Environmental Studies, 78(3), 365–381.

4. Kim, Y. M., Bouras, N., Kav, N. N. V., & Strelkov, S. E. (2010). Inhibition of photosynthesis and modification of the wheat leaf proteome by Ptr ToxB: A host‐specific toxin from the fungal pathogen Pyrenophora tritici‐repentis. Proteomics, 10(16), 2911–2926.

5. Meklat, A., Bouras, N., Zitouni, A., Mathieu, F., Lebrihi, A., Schumann, P., & Sabaou, N. (2012). Actinopolyspora algeriensis sp. nov., a novel halophilic actinomycete isolated from a Saharan soil. Extremophiles, 16(5), 771–776.

 

Sunny Kumar | Nanobiotechnology | Young Scientist Award

Mr. Sunny Kumar | Nanobiotechnology | Young Scientist Award

Researcher, CSIR-Indian Institute Of Chemical Biology, India

Mr. Sunny Kumar is an emerging researcher in cancer biology and nanomedicine, recognized for his interdisciplinary contributions that bridge molecular oncology, tumor microenvironment studies, and nanotechnology-driven therapeutics. With an h-index of 6, 11 publications, and 148 citations (as indexed in Scopus), his research reflects both productivity and impact within translational cancer science. His primary research focuses on elucidating the molecular mechanisms underlying glioma, colorectal, and breast cancer progression, emphasizing protein quality control systems such as the ubiquitin-proteasome system and their regulatory influence on oncogenic signaling. Mr. Sunny Kumar has explored novel therapeutic targets like E3 ligases (CHIP), PD-1/PD-L1 pathways, and HAUSP-MDM2 axes, offering valuable insights for cancer immunotherapy and personalized treatment strategies. In addition to mechanistic studies, Mr. Sunny Kumar integrates nanobiotechnology and drug delivery innovation, developing nanoparticle-based formulations capable of crossing the blood–brain barrier for targeted glioma therapy. His research on dual-drug nanotherapeutics and carbon nanotube-based diagnostic platforms has contributed to the advancement of precision medicine approaches for difficult-to-treat cancers. He has published extensively as first or corresponding author in high-impact journals such as Genes & Diseases (IF 9.4), BBA-Molecular Cell Research (IF 3.7), International Journal of Pharmaceutics (IF 5.2), and Journal of Medicinal Chemistry (IF 6.8). His scholarly output also includes multiple book chapters with Springer and Taylor & Francis, covering cancer proteomics, personalized therapy, and nanotherapeutics. Mr. Sunny Kumar serves as a peer reviewer for reputed journals, including BBA–Reviews on Cancer and Experimental Cell Research, further demonstrating his engagement in the scientific community. His research exhibits a robust methodological framework, integrating cell and molecular biology, bioinformatics, animal models, and nanocarrier engineering. Collectively, Mr. Sunny Kumar’s scientific endeavors underscore a commitment to next-generation cancer therapeutics, aiming to translate molecular discoveries into clinically viable nanomedicine solutions for precision oncology.

Profile: Scopus | ORCID | Google Scholar | RsearchGate

Featured Publications

1. Kumar, S., Chatterjee, M., Ghosh, P., Ganguly, K. K., Basu, M., & Ghosh, M. K. (2023). Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients. Genes & Diseases, 10(4), 1318–1350.

2. Kumar, S., Basu, M., & Ghosh, M. K. (2022). Chaperone-assisted E3 ligase CHIP: A double agent in cancer. Genes & Diseases, 9(6), 1521–1555.

3. Kumar, S., Basu, M., Ghosh, P., Ansari, A., & Ghosh, M. K. (2023). COVID‐19: Clinical status of vaccine development to date. British Journal of Clinical Pharmacology, 89(1), 114–149.

4. Kumar, S., Basu, M., Ghosh, P., Pal, U., & Ghosh, M. K. (2023). COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery. Genes & Diseases, 10(4), 1402–1428.

5. Ghosh, M. K., Kumar, S., Ganguly, K. K., Ghosh, P., Tabassum, S., Basu, B., & Basu, M. (2023). COVID-19 and cancer: Insights into their association and influence on genetic and epigenetic landscape. Epigenomics, 15(4), 227–248.